Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer, February 2022

Free Subscription


Abstracts

Retrieve all available abstracts of the following 306 articles:
HTML format


 

Single Articles

  1. SBIZZERA M, Descotes F, Arber T, Neuville P, et al
    Bladder cancer detection in patients with neurogenic bladder: are cystoscopy and cytology effective, and are biomarkers pertinent as future diagnostic tools? A scoping review.
    World J Urol. 2022 Feb 4. pii: 10.1007/s00345-022-03943.
    PubMed    
    Abstract available

  2. DEB AA, Agag A, Naushad N, Krishnamoorthy R, et al
    Chemoresection by mitomycin C compared to transurethral resection of bladder tumor in patients with recurrent nonmuscle-invasive bladder cancer: A systematic review and meta-analysis.
    Turk J Urol. 2021;47:260-269.
    PubMed    
    Abstract available

  3. YANG Y, Yan X, Li J, Liu C, et al
    CD47-targeted optical molecular imaging and near-infrared photoimmunotherapy in the detection and treatment of bladder cancer.
    Mol Ther Oncolytics. 2022;24:319-330.
    PubMed    
    Abstract available

  4. ZHOU Q, Zhang Z, Ang X, Zhang H, et al
    A nomogram combined with radiomics features, albuminuria, and metabolic syndrome to predict the risk of myometrial invasion of bladder cancer.
    Transl Cancer Res. 2021;10:3177-3191.
    PubMed    
    Abstract available

  5. LU JL, Xia QD, Liu CQ, Sun JX, et al
    Efficacy and toxicity in scheduled intravesical gemcitabine versus Bacille Calmette-Guerin for Ta and T1 bladder cancer: a systematic review and meta-analysis.
    Transl Cancer Res. 2021;10:2849-2858.
    PubMed    
    Abstract available

  6. FENG D, Song P, Yang Y, Wei W, et al
    Is metabolic syndrome associated with high tumor grade and stage of bladder cancer: a systematic review and meta-analysis.
    Transl Cancer Res. 2021;10:2188-2198.
    PubMed    
    Abstract available

  7. LI X, Wu Y, Yuan Y
    Gene network screening of bladder cancer via modular analysis.
    Transl Cancer Res. 2021;10:1043-1052.
    PubMed    
    Abstract available

  8. ONG K, Dyer J, Wilson M, Hayne D, et al
    Urethral fistula and perineal collection during intravesical treatment for non-muscle invasive bladder cancer - A rare complication.
    Urol Case Rep. 2022;42:102003.
    PubMed    
    Abstract available

  9. LI ZJ, Wang DY, Liu ZH
    Clinical Efficacy and Quality of Life Assessment of Partial Cystectomy and Plasmakinetic Transurethral Resection of Tumor in Bladder Cancer Patients.
    Cancer Manag Res. 2022;14:389-398.
    PubMed    
    Abstract available

  10. ZHU RJ, Zhou J, Liang PQ, Xiang XX, et al
    Accuracy of cytokeratin 19 fragment in the diagnosis of bladder cancer.
    Biomark Med. 2022 Feb 3. doi: 10.2217/bmm-2021-0754.
    PubMed    
    Abstract available

  11. ALGHAFEES MA, Alqahtani MA, Musalli ZF, Alasker A, et al
    Bladder cancer in Saudi Arabia: a registry-based nationwide descriptive epidemiological and survival analysis.
    Ann Saudi Med. 2022;42:17-28.
    PubMed    
    Abstract available

  12. MALIK K, Raja A, Ravishankar LS, Narayanaswamy K, et al
    Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Non-muscle Invasive Bladder Cancers: Long-term Results of a Modified Schedule.
    Indian J Surg Oncol. 2021;12:796-801.
    PubMed    
    Abstract available

  13. ATHER MH
    What after BCG Fails in Non-muscle Invasive Bladder Cancer?
    J Coll Physicians Surg Pak. 2022;32:139-140.
    PubMed    
    Abstract available

  14. OMURA M, Kikuchi E, Shigeta K, Ogihara K, et al
    Potential therapeutic effects of adjuvant chemotherapy after neoadjuvant chemotherapy for locally advanced muscle-invasive bladder cancer.
    Jpn J Clin Oncol. 2022 Feb 1. pii: 6518269. doi: 10.1093.
    PubMed    
    Abstract available

  15. MARTINI A, Lonati C, Montorsi F, Briganti A, et al
    The Role of Prior Bladder Cancer on Recurrence in Patients Treated with Radical Nephroureterectomy.
    Clin Genitourin Cancer. 2021 Dec 11. pii: S1558-7673(21)00236.
    PubMed    
    Abstract available

  16. LUO Y, He Z, Liu W, Zhou F, et al
    DTL Is a Prognostic Biomarker and Promotes Bladder Cancer Progression through Regulating the AKT/mTOR axis.
    Oxid Med Cell Longev. 2022;2022:3369858.
    PubMed    
    Abstract available

  17. BERTOLASO P, Brouste V, Cazeau AL, de Clermont-Gallerande H, et al
    Impact of (18) FDG- PET CT in the Management of Muscle Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2022 Jan 14. pii: S1558-7673(22)00020.
    PubMed    
    Abstract available

  18. ZHANG LH, Zhang WY, Xiong JM, Duan XM, et al
    Mechanisms of Compound Kushen Injection for the treatment of bladder cancer based on bioinformatics and network pharmacology with experimental validation.
    Chin J Nat Med. 2022;20:43-53.
    PubMed    
    Abstract available

  19. CHEN H, Hong Y, Yu B, Ruiqian L, et al
    Retrospective analysis of bladder cancer morphology and depth of invasion under cystoscopy.
    BMC Urol. 2022;22:12.
    PubMed    
    Abstract available

  20. KOOL R, Yanev I, Hijal T, Vanhuyse M, et al
    Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Canadian cost-effectiveness analysis.
    Can Urol Assoc J. 2022 Jan 27. pii: cuaj.7430. doi: 10.5489/cuaj.7430.
    PubMed    
    Abstract available

  21. BHINDI B, Kool R, Kulkarni GS, Siemens DR, et al
    Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Abridged version.
    Can Urol Assoc J. 2021;15:230-239.
    PubMed    


  22. KOOL R, Marcq G, Shinde-Jadhav S, Mansure JJ, et al
    Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy.
    Eur Urol Open Sci. 2021;36:26-33.
    PubMed    
    Abstract available

  23. WU JH, Sun KN, Chen ZH, He YJ, et al
    Exosome-Mediated miR-4792 Transfer Promotes Bladder Cancer Cell Proliferation via Enhanced FOXC1/c-Myc Signaling and Warburg Effect.
    J Oncol. 2022;2022:5680353.
    PubMed    
    Abstract available

  24. SELL V, Ettala O, Perez IM, Jarvinen R, et al
    Awareness of Smoking as a Risk Factor in Bladder Cancer: Results from the Prospective FinnBladder 9 Trial.
    Eur Urol Focus. 2022 Jan 27. pii: S2405-4569(22)00035.
    PubMed    
    Abstract available

  25. KIDA N, Morishima T, Tsubakihara Y, Miyashiro I, et al
    Stage at Diagnosis and Prognosis of Colorectal, Stomach, Lung, Liver, Kidney, and Bladder Cancers in Dialysis Patients: A Multicenter Retrospective Study Using Cancer Registry Data and Administrative Data.
    Nephron. 2022 Jan 28:1-10. doi: 10.1159/000521603.
    PubMed    
    Abstract available

  26. KANMALAR M, Abdul Sani SF, Kamri NINB, Said NABM, et al
    Raman spectroscopy biochemical characterisation of bladder cancer cisplatin resistance regulated by FDFT1: a review.
    Cell Mol Biol Lett. 2022;27:9.
    PubMed    
    Abstract available

  27. BOTHIG R, Rosenbaum C, Bohme H, Kowald B, et al
    Special surgical aspects of radical cystectomy in spinal cord injury patients with bladder cancer.
    World J Urol. 2022 Jan 29. pii: 10.1007/s00345-022-03939.
    PubMed    
    Abstract available

  28. MAMDOUH S, Khorshed F, Hammad G, Elesaily K, et al
    Molecular Detection of Genetic Susceptibility to Bladder Cancer in Egyptian Patients.
    Asian Pac J Cancer Prev. 2022;23:221-232.
    PubMed    
    Abstract available

  29. TANG F, Li Z, Lai Y, Lu Z, et al
    A 7-gene signature predicts the prognosis of patients with bladder cancer.
    BMC Urol. 2022;22:8.
    PubMed    
    Abstract available

  30. SHIGA M, Nishiyama H
    [. Current Understanding of Mechanism of BCG Failure, and the Status of Drug Development Using BCG Cell Wall Components].
    Gan To Kagaku Ryoho. 2022;49:43-46.
    PubMed    


  31. ALLAMEH F, Sangian A, Razaghi M, Razzaghi Z, et al
    Comparison of various types of lasers and transurethral resection in the treatment of bladder tumors: a systematic review and meta-analysis.
    Lasers Med Sci. 2022;37:95-101.
    PubMed    
    Abstract available

  32. PALACKA P, Gvozdjakova A, Rausova Z, Kucharska J, et al
    Platelet Mitochondrial Bioenergetics Reprogramming in Patients with Urothelial Carcinoma.
    Int J Mol Sci. 2021;23.
    PubMed    
    Abstract available

  33. BELL CJ, Potts KG, Hitt MM, Pink D, et al
    Novel colchicine derivative CR42-24 demonstrates potent anti-tumor activity in urothelial carcinoma.
    Cancer Lett. 2022;526:168-179.
    PubMed    
    Abstract available

  34. OU L, Luo J, Wei Z, Zheng A, et al
    Urachal tuberculosis with invasion of the bladder wall: A case report and literature review.
    Actas Urol Esp (Engl Ed). 2022;46:1-3.
    PubMed    


  35. KAWADA T
    Sex difference in survival in patients with radical cystectomy.
    Urol Oncol. 2022;40:67.
    PubMed    


  36. WESTERDAHL JS, Grant J, Sontheimer R, Zussman J, et al
    Darier disease, radiation therapy, and herpesvirus -- an unfortunate triad.
    Dermatol Online J. 2021;27.
    PubMed    
    Abstract available

  37. PARMAR KM, Thummala Y, Kumar S, Singh P, et al
    Utility of FDG-PET CT scan to detect an incidental rare recurrence of carcinoma urinary bladder following radical cystectomy.
    BMJ Case Rep. 2021;14.
    PubMed    


  38. MADHUMITHA B, Joseph LD, Archana B, Chandru T, et al
    Urothelial carcinoma with divergent differentiation in a horseshoe kidney.
    Indian J Pathol Microbiol. 2021;64:866-867.
    PubMed    


  39. KRISHNAMURTHY S, Menon M, Parameswaran A, Sivaraman A, et al
    A case of solitary fibrous tumor of urinary bladder.
    Indian J Pathol Microbiol. 2021;64:847-849.
    PubMed    


  40. YAO X, Liu H, Xu H
    The Impact of Metformin Use with Survival Outcomes in Urologic Cancers: A Systematic Review and Meta-Analysis.
    Biomed Res Int. 2021;2021:5311828.
    PubMed    
    Abstract available

  41. MOLLICA V, Rizzo A, Massari F
    Re: Thomas Powles, Tibor Csoszi, Mustafa Ozguroglu, et al. Pembrolizumab Alone or Combined with Chemotherapy Versus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-label, Phase 3 Trial. Lancet Onc
    Eur Urol Oncol. 2021;4:854.
    PubMed    


  42. LI F, Wang Y, Xie K, Fang Y, et al
    The efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating advanced urothelial cancer: a meta-analysis of clinical trials.
    Aging (Albany NY). 2021;13:20468-20480.
    PubMed    
    Abstract available

  43. BURATIN A, Gaffo E, Dal Molin A, Bortoluzzi S, et al
    CircIMPACT: An R Package to Explore Circular RNA Impact on Gene Expression and Pathways.
    Genes (Basel). 2021;12.
    PubMed    
    Abstract available

  44. REDDY AG, Sparks AD, Darwish C, Whalen MJ, et al
    Oncologic Outcomes for Robotic Vs. Open Radical Cystectomy Among Locally Advanced and Node-Positive Patients: Analysis of The National Cancer Database.
    Clin Genitourin Cancer. 2021;19:547-553.
    PubMed    
    Abstract available

  45. FENG C, Wang Y, Dan G, Zhong Z, et al
    Evaluation of a fractional-order calculus diffusion model and bi-parametric VI-RADS for staging and grading bladder urothelial carcinoma.
    Eur Radiol. 2022;32:890-900.
    PubMed    
    Abstract available

  46. KHALIFE N, Chahine C, Kordahi M, Felefly T, et al
    Urothelial carcinoma in the era of immune checkpoint inhibitors.
    Immunotherapy. 2021;13:953-964.
    PubMed    
    Abstract available

  47. LAUKHTINA E, Mori K, Mostafaei H, Merseburger AS, et al
    Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis.
    Immunotherapy. 2021;13:917-929.
    PubMed    
    Abstract available

  48. WONG JL, Rosenberg JE
    Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.
    Expert Opin Biol Ther. 2021;21:863-873.
    PubMed    
    Abstract available

  49. JAIN RK, Skelton Iv WP, Pond GR, Naqvi M, et al
    Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma.
    Clin Genitourin Cancer. 2021;19:540-546.
    PubMed    
    Abstract available

  50. RIZZO A, Mollica V, Massari F
    Re: Thomas Powles, Jonathan E. Rosenberg, Guru P. Sonpavde, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med 2021;384:1125-35.
    Eur Urol Oncol. 2021;4:670.
    PubMed    


  51. HOFFMAN-CENSITS JH, Lombardo KA, Parimi V, Kamanda S, et al
    Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes.
    Appl Immunohistochem Mol Morphol. 2021;29:619-625.
    PubMed    
    Abstract available

  52. PATEL SY, Trona N, Alford B, Laborde JM, et al
    Preoperative immunonutrition and carbohydrate loading associated with improved bowel function after radical cystectomy.
    Nutr Clin Pract. 2022;37:176-182.
    PubMed    
    Abstract available

  53. BOREA R, Damassi A, Rebuzzi SE, Banna GL, et al
    Immunotherapy retreatment: case report, review of the literature and proposal for the definition of different scenarios.
    Immunotherapy. 2021;13:645-652.
    PubMed    
    Abstract available

  54. SZABADOS B, Prendergast A, Jackson-Spence F, Choy J, et al
    Immune Checkpoint Inhibitors in Front-line Therapy for Urothelial Cancer.
    Eur Urol Oncol. 2021;4:943-947.
    PubMed    
    Abstract available

  55. KHAKI AR, Li A, Diamantopoulos LN, Miller NJ, et al
    A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
    Eur Urol Oncol. 2021;4:464-472.
    PubMed    
    Abstract available

  56. MAAS M, Stuhler V, Walz S, Stenzl A, et al
    Enfortumab vedotin - next game-changer in urothelial cancer.
    Expert Opin Biol Ther. 2021;21:801-809.
    PubMed    
    Abstract available

  57. COLLA RUVOLO C, Nocera L, Stolzenbach LF, Wenzel M, et al
    Incidence and Survival Rates of Contemporary Patients with Invasive Upper Tract Urothelial Carcinoma.
    Eur Urol Oncol. 2021;4:792-801.
    PubMed    
    Abstract available

  58. RAVI P, McGregor BA
    Antibody-drug conjugates for the treatment of urothelial carcinoma.
    Expert Opin Biol Ther. 2021;21:915-922.
    PubMed    
    Abstract available

  59. BROOKS N, Nagaraju S, Matulay J, Han XY, et al
    Bacillus Calmette-Guerin Retains Clinically Relevant Viability for up to 72 Hours After Reconstitution: Potential Implications for Clinical Practice in Times of Shortage.
    Eur Urol Oncol. 2021;4:826-828.
    PubMed    
    Abstract available

  60. SHARIAT S, Gontero P, Catto JWF
    How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder?
    Eur Urol Oncol. 2021;4:663-669.
    PubMed    
    Abstract available

  61. BURGER M, Kamat AM, McConkey D
    Does Variant Histology Change Management of Non-muscle-invasive Bladder Cancer?
    Eur Urol Oncol. 2021;4:510-514.
    PubMed    
    Abstract available

  62. STENZL A, McConkey D, Bellmunt J
    Does it matter whether a T1 high-grade tumor is molecularly classified?
    Eur Urol Oncol. 2021;4:837-842.
    PubMed    
    Abstract available

  63. LAM JM, Liu WK, Powles T, Tang YZ, et al
    Single-centre Experience of Patients with Metastatic Urothelial Cancer Treated with Chemotherapy Following Immune Checkpoint Inhibition.
    Eur Urol Oncol. 2021;4:659-662.
    PubMed    
    Abstract available

  64. TAMAI M, Tatarano S, Okamura S, Fukumoto W, et al
    microRNA-99a-5p induces cellular senescence in gemcitabine-resistant bladder cancer by targeting SMARCD1.
    Mol Oncol. 2022 Feb 11. doi: 10.1002/1878-0261.13192.
    PubMed    
    Abstract available

  65. LIU J, Zhang Z, Zhang W, Meng L, et al
    Ferroptosis Mediation Patterns Reveal Novel Tool to Implicate Immunotherapy and Multi-Omics Characteristics in Bladder Cancer.
    Front Cell Dev Biol. 2022;10:791630.
    PubMed    
    Abstract available

  66. PAGLIARULO F, Cheng PF, Brugger L, van Dijk N, et al
    Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer.
    Front Immunol. 2022;12:793992.
    PubMed    
    Abstract available

  67. TOMIDA R, Miyake M, Minato R, Sawada Y, et al
    Impact of carcinoma in situ on the outcome of intravesical Bacillus Calmette-Guerin therapy for non-muscle-invasive bladder cancer: a comparative analysis of large real-world data.
    Int J Clin Oncol. 2022 Feb 10. pii: 10.1007/s10147-022-02127.
    PubMed    
    Abstract available

  68. AFFERI L, Lonati C, Montorsi F, Briganti A, et al
    Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancer.
    World J Urol. 2022 Feb 10. pii: 10.1007/s00345-022-03948.
    PubMed    
    Abstract available

  69. CHEN K, Zhu S, Yu W, Xia Y, et al
    Comprehensive Analysis of N6-Methylandenosine-Related Long Non-Coding RNAs Signature in Prognosis and Tumor Microenvironment of Bladder Cancer.
    Front Oncol. 2022;12:774307.
    PubMed    
    Abstract available

  70. PENG S, Ma S, Yang F, Xu C, et al
    Prognostic value and underlying mechanism of autophagy-related genes in bladder cancer.
    Sci Rep. 2022;12:2219.
    PubMed    
    Abstract available

  71. MICHEL F, Cancrini F, Cancel-Tassin G, Game X, et al
    A study of the immunohistochemical profile of bladder cancer in neuro-urological patients by the French Association of Urology.
    World J Urol. 2022 Feb 9. pii: 10.1007/s00345-022-03942.
    PubMed    
    Abstract available

  72. SCHIERZ JH, McLeod A, Ali F
    Rare osteoarticular complications on [18F]FDG-PET/CT - following intravesical BCG immunotherapy for bladder cancer.
    Nucl Med Rev Cent East Eur. 2022;25:68-69.
    PubMed    
    Abstract available

  73. NERLI RB, Ghagane SC, Rangrez SS, Chandra S, et al
    Author Reply Re: Nerli RB, Ghagane SC, Rangrez S, Chandra S, Thakur ML, Gomella L. Detection of bladder cancer using voided urine sample and by targeting genomic VPAC receptors. Indian J Urol 2021;37:345-9.
    Indian J Urol. 2022;38:78-79.
    PubMed    


  74. PATTNAIK SS
    Re: Nerli RB, Ghagane SC, Rangrez S, Chandra S, Thakur ML, Gomella L. Detection of bladder cancer using voided urine sample and by targeting genomic VPAC receptors. Indian J Urol 2021;37:345-9.
    Indian J Urol. 2022;38:77-78.
    PubMed    


  75. WETTSTEIN MS, Baxter NN, Sutradhar R, Mamdani M, et al
    Uptake of re-resection in T1 bladder cancer: An interrupted population-based time series analysis among different groups of surgeons.
    Urol Oncol. 2022 Feb 5. pii: S1078-1439(21)00553.
    PubMed    
    Abstract available

  76. OKAMOTO T, Yamamoto K, Kanomata N
    Metastatic Rectal Linitis Plastic From Bladder Cancer.
    Am J Gastroenterol. 2021;116:2324.
    PubMed    


  77. MOHSENZADEGAN M, Razmi M, Vafaei S, Abolhasani M, et al
    Publisher Correction: Co-expression of cancer-testis antigens of MAGE-A6 and MAGE-A11 is associated with tumor aggressiveness in patients with bladder cancer.
    Sci Rep. 2022;12:2330.
    PubMed    


  78. AL-ZUBAIDI M, McCombie S, Swarbrick N, Hayne D, et al
    Unique case of IgG4-related disease of the renal pelvis involving the inferior vena cava masquerading as locally advanced urothelial cancer.
    BMJ Case Rep. 2022;15.
    PubMed    
    Abstract available

  79. SHI ZD, Hao L, Han XX, Wu ZX, et al
    Targeting HNRNPU to overcome cisplatin resistance in bladder cancer.
    Mol Cancer. 2022;21:37.
    PubMed    
    Abstract available

  80. BOOT IWA, Wesselius A, Yu EYW, Brinkman M, et al
    Dietary B group vitamin intake and the bladder cancer risk: a pooled analysis of prospective cohort studies.
    Eur J Nutr. 2022 Feb 7. pii: 10.1007/s00394-022-02805.
    PubMed    
    Abstract available

  81. PRESS RH, Shelton JW, Zhang C, Dang Q, et al
    Bone Marrow Suppression during Postoperative Radiation for Bladder Cancer and Comparative Benefit of Proton Therapy-Phase 2 Trial Secondary Analysis.
    Int J Part Ther. 2021;8:1-10.
    PubMed    
    Abstract available

  82. ZHANG S, Wang Q, Li W, Chen J, et al
    MIR100HG Regulates CALD1 Gene Expression by Targeting miR-142-5p to Affect the Progression of Bladder Cancer Cells in vitro, as Revealed by Transcriptome Sequencing.
    Front Mol Biosci. 2022;8:793493.
    PubMed    
    Abstract available

  83. LU X, Jiang H, Wang D, Wang Y, et al
    Early Warning Models to Predict the 90-Day Urinary Tract Infection Risk After Radical Cystectomy and Urinary Diversion for Patients With Bladder Cancer.
    Front Surg. 2022;8:782029.
    PubMed    
    Abstract available

  84. SONG Y, Du Y, Qin C, Liang H, et al
    Gemcitabine-Resistant Biomarkers in Bladder Cancer are Associated with Tumor-Immune Microenvironment.
    Front Cell Dev Biol. 2022;9:809620.
    PubMed    
    Abstract available

  85. HU J, Zheng Z, Zheng J, Xie W, et al
    A Model for Identifying Optimal Patients for Primary Tumor Resection in Patients With Metastatic Bladder Cancer.
    Front Oncol. 2022;11:809664.
    PubMed    
    Abstract available

  86. WANG DQ, Shuai J, Zheng H, Guo ZQ, et al
    Can Routine Blood and Urine Parameters Reveal Clues to Detect Bladder Cancer? A Case-Control Study.
    Front Oncol. 2022;11:796975.
    PubMed    
    Abstract available

  87. ZHANG Y, Lin Y, Lv D, Wu X, et al
    Identification and validation of a novel signature for prediction the prognosis and immunotherapy benefit in bladder cancer.
    PeerJ. 2022;10:e12843.
    PubMed    
    Abstract available

  88. XU C, Zhou G, Sun Z, Zhang Z, et al
    miR-148a-3p inhibits the proliferation and migration of bladder cancer via regulating the expression of ROCK-1.
    PeerJ. 2022;10:e12724.
    PubMed    
    Abstract available

  89. ZHANG C, Wang YQ, Jin G, Wu S, et al
    Erratum: Selection of reference genes for gene expression studies in human bladder cancer using SYBR-Green quantitative polymerase chain reaction.
    Oncol Lett. 2022;23:85.
    PubMed    
    Abstract available

  90. HUANG L, Zhang X, Li F, Wang X, et al
    MicroRNA-143-3p/TBX3 Axis Represses Malignant Cell Behaviors in Bladder Cancer.
    Comput Math Methods Med. 2022;2022:2880087.
    PubMed    
    Abstract available

  91. ZHU K, Liu X, Deng W, Wang G, et al
    Identification of a chromatin regulator signature and potential candidate drugs for bladder cancer.
    Hereditas. 2022;159:13.
    PubMed    
    Abstract available

  92. BANGASH M, Faruqui N, Muhammad AU, Uddin Z, et al
    Leiomyoma Urinary Bladder, Mimicking Urothelial Cancer.
    J Ayub Med Coll Abbottabad. 2021;33:685-689.
    PubMed    
    Abstract available

  93. JORDAN SR, Geiger CL, Fischer SM, Kessler ER, et al
    Care planning priorities of older patients with advanced bladder cancer.
    J Geriatr Oncol. 2022 Feb 2. pii: S1879-4068(22)00011.
    PubMed    
    Abstract available

  94. YU C, Zhang Y, Wang N, Wei W, et al
    Treatment of bladder cancer by geoinspired synthetic chrysotile nanocarrier-delivered circPRMT5 siRNA.
    Biomater Res. 2022;26:6.
    PubMed    
    Abstract available

  95. HENTSCHEL AE, Beijert IJ, Bosschieter J, Kauer PC, et al
    Bladder cancer detection in urine using DNA methylation markers: a technical and prospective preclinical validation.
    Clin Epigenetics. 2022;14:19.
    PubMed    
    Abstract available

  96. ASGHARIAZAR V, Kadkhodayi M, Mansoori B, Mohammadi A, et al
    Restoration of miR-143 reduces migration and proliferation of bladder cancer cells by regulating signaling pathways involved in EMT.
    Mol Cell Probes. 2022;61:101794.
    PubMed    
    Abstract available

  97. MOSCHINI M, Gandaglia G, Deho F, Salonia A, et al
    Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up.
    Ann Oncol. 2022 Feb 1. pii: S0923-7534(22)00102.
    PubMed    


  98. TOMITA Y, Yamamoto Y, Tsuchiya N, Kanayama H, et al
    Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis.
    Int J Clin Oncol. 2022;27:383-395.
    PubMed    
    Abstract available

  99. PINARD CJ, Hocker SE, Poon AC, Inkol JM, et al
    Evaluation of PD-1 and PD-L1 expression in canine urothelial carcinoma cell lines.
    Vet Immunol Immunopathol. 2022;243:110367.
    PubMed    
    Abstract available

  100. SCHNEIDER AK, Teuschler T, Wolko S
    [Care after radical cystectomy].
    Urologe A. 2022;61:83-86.
    PubMed    


  101. ZENGIN ZB, Chehrazi-Raffle A, Salgia NJ, Muddasani R, et al
    Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma.
    Urol Oncol. 2022;40:25-36.
    PubMed    
    Abstract available

  102. LI L, Na R, Mi T, Cheng H, et al
    Medical Image Diagnostic Value of Computed Tomography for Bladder Tumors.
    Comput Math Methods Med. 2021;2021:3781028.
    PubMed    
    Abstract available

  103. LI S, Liu X, Chen X
    Development and validation of a prognostic nomogram for predicting overall survival in patients with primary bladder sarcoma: a SEER-based retrospective study.
    BMC Urol. 2021;21:162.
    PubMed    
    Abstract available

  104. TUO Z, Zhang Y, Wang J, Zhou H, et al
    Three-port approach vs standard laparoscopic radical cystectomy with an ileal conduit: a single-centre retrospective study.
    BMC Urol. 2021;21:159.
    PubMed    
    Abstract available

  105. TURNER LD, Trinh CH, Hubball RA, Orritt KM, et al
    From Fragment to Lead: De Novo Design and Development toward a Selective FGFR2 Inhibitor.
    J Med Chem. 2022;65:1481-1504.
    PubMed    
    Abstract available

  106. INOUE K, Fukuhara H, Yamamoto S, Karashima T, et al
    Current status of photodynamic technology for urothelial cancer.
    Cancer Sci. 2022;113:392-398.
    PubMed    
    Abstract available

  107. CACCIAMANI GE, Matulewicz RS, Kumar R, Teoh JY, et al
    Fighting the 'tobacco epidemic' - A call to action to identify Targeted Intervention Points (TIPs) for better counseling patients with urothelial cancer.
    Urol Oncol. 2021;39:793-796.
    PubMed    
    Abstract available

  108. GRUNEWALD CM, Niegisch G
    [Circulating tumor DNA (ctDNA) in urothelial carcinoma-the long-desired biomarker?]
    Urologe A. 2021;60:1466-1467.
    PubMed    


  109. BETANCOURT RL, Samulski DT
    Endometrial adenocarcinoma presenting in a voided urine cytology specimen: Case report.
    Diagn Cytopathol. 2021 Aug 19. doi: 10.1002/dc.24838.
    PubMed    
    Abstract available

  110. DURSUN F, Mackay A, Guzman JCA, Wenker E, et al
    Utilization and outcomes of metastasectomy for patients with metastatic urothelial cancer: An analysis of the national cancer database.
    Urol Oncol. 2022;40:61.
    PubMed    
    Abstract available

  111. SOOD A, Keeley J, Palma-Zamora I, Novara G, et al
    High-intensity local treatment of clinical node-positive urothelial carcinoma of the bladder alongside systemic chemotherapy improves overall survival.
    Urol Oncol. 2022;40:62.
    PubMed    
    Abstract available

  112. LI CF, Chan TC, Pan CT, Vejvisithsakul PP, et al
    EMP2 induces cytostasis and apoptosis via the TGFbeta/SMAD/SP1 axis and recruitment of P2RX7 in urinary bladder urothelial carcinoma.
    Cell Oncol (Dordr). 2021;44:1133-1150.
    PubMed    
    Abstract available

  113. NGUYEN A, Fassas S, Freidberg N, Sullo E, et al
    Recurrence and treatment of adult primary nonmetastatic bladder rhabdomyosarcoma: A systematic review.
    Urol Oncol. 2021;39:774-780.
    PubMed    
    Abstract available

  114. LE BRUN IC, Benderra MA
    [New approval: Avelumab - maintenance therapy for advanced or metastatic urothelial carcinoma].
    Bull Cancer. 2021;108:784-786.
    PubMed    


  115. GHANDOUR RA, Freifeld Y, Cheaib J, Singla N, et al
    Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma.
    Urol Oncol. 2021;39:788.
    PubMed    
    Abstract available

  116. CHEN H, Wang M, Weng T, Wei Y, et al
    The prognostic and clinicopathological significance of Tim-3 and PD-1 expression in the prognosis of upper urinary tract urothelial carcinoma.
    Urol Oncol. 2021;39:743-753.
    PubMed    
    Abstract available

  117. COLLA RUVOLO C, Wenzel M, Nocera L, Wurnschimmel C, et al
    The effect of race on stage at presentation and survival in upper tract urothelial carcinoma.
    Urol Oncol. 2021;39:788.
    PubMed    
    Abstract available

  118. ISHIYAMA Y, Kondo T, Nemoto Y, Kobari Y, et al
    Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma.
    Urol Oncol. 2021;39:834.
    PubMed    
    Abstract available

  119. TACHIBANA I, Calaway AC, Abedali Z, Szymanski KM, et al
    Definitive surgical therapy for refractory radiation cystitis: Evaluating effectiveness, tolerability, and extent of surgical approach.
    Urol Oncol. 2021;39:789.
    PubMed    
    Abstract available

  120. KOBAYASHI T, Ito K, Kojima T, Maruyama S, et al
    Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR.
    Cancer Immunol Immunother. 2022;71:461-471.
    PubMed    
    Abstract available

  121. MATSUMOTO A, Matsui I, Mano K, Mizuno H, et al
    Recurrent membranous nephropathy with a possible alteration in the etiology: a case report.
    BMC Nephrol. 2021;22:253.
    PubMed    
    Abstract available

  122. AJIB K, Berjaoui MB, Herrera-Caceres J, Nason G, et al
    Characterization and management of NMIBC recurrences after TMT: a matched cohort analysis.
    Urol Oncol. 2021;39:835.
    PubMed    
    Abstract available

  123. RUVOLO CC, Nocera L, Stolzenbach FL, Wenzel M, et al
    Contemporary analysis of the effect of marital status on survival in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: A population-based study.
    Urol Oncol. 2021;39:789.
    PubMed    
    Abstract available

  124. HUBERT P, Selmani Z, Loriot Y, Thiery-Vuillemin A, et al
    FGFR alterations in urothelial carcinoma: Picking the right target.
    Bull Cancer. 2021;108:566-570.
    PubMed    


  125. MILOJEVIC B, Dzamic Z, Grozdic Milojevic I, Bumbasirevic U, et al
    Prognostic value of Balkan endemic nephropathy and gender on upper tract urothelial carcinoma outcomes after radical nephroureterectomy: A cohort study.
    Urol Oncol. 2021;39:786.
    PubMed    
    Abstract available

  126. NICHOLS MM, Reynolds JP, McKenney JK, Nicolas MM, et al
    Urine cytology findings in patients with biopsy-confirmed urothelial carcinoma in situ with plasmacytoid features.
    Cancer Cytopathol. 2021;129:798-804.
    PubMed    
    Abstract available

  127. OKITA K, Hatakeyama S, Hagiwara K, Suzuki Y, et al
    The effect of number of treatment cycles of platinum-based first-line chemotherapy on maximum radiological response in patients with advanced urothelial carcinoma.
    Urol Oncol. 2021;39:832.
    PubMed    
    Abstract available

  128. RODRIGUES PESSOA R, Morrison JC, Konety B, Gershman B, et al
    National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy.
    Urol Oncol. 2021;39:832.
    PubMed    
    Abstract available

  129. KIM HD, Im HS, Kim JH, Jeong H, et al
    Use of Gemcitabine plus Carboplatin is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4-5.
    Cancer Res Treat. 2021;53:1166-1173.
    PubMed    
    Abstract available

  130. MOREIRA I, Coelho S, Rodrigues A, Patrao AS, et al
    Urachal carcinoma: A case of a rare neoplasm.
    Curr Probl Cancer. 2021;45:100711.
    PubMed    
    Abstract available

  131. LIU L, Zhu J, Tian Y
    Carcinosarcoma is an aggressive subtype of bladder cancer: A population-based study.
    Cancer Med. 2022 Feb 18. doi: 10.1002/cam4.4611.
    PubMed    
    Abstract available

  132. KACHANOV M, Vetterlein MW, Soave A, Karakiewicz PI, et al
    Oncologic impact of concomitant prostate cancer characteristics at the time of radical cystoprostatectomy for bladder cancer: a population-based analysis.
    Aging Male. 2022;25:54-61.
    PubMed    
    Abstract available

  133. HAGIMOTO H, Makita N, Mine Y, Kokubun H, et al
    Correction to: Comparison between 5-aminolevulinic acid photodynamic diagnosis and narrow-band imaging for bladder cancer detection.
    BMC Urol. 2022;22:23.
    PubMed    


  134. ZHANG S, Zhang J, Zhang Q, Liang Y, et al
    Identification of Prognostic Biomarkers for Bladder Cancer Based on DNA Methylation Profile.
    Front Cell Dev Biol. 2022;9:817086.
    PubMed    
    Abstract available

  135. XU J, Zeng S, Li J, Gao L, et al
    Novel Non-Invasive Diagnosis of Bladder Cancer in Urine Based on Multifunctional Nanoparticles.
    Front Cell Dev Biol. 2022;9:813420.
    PubMed    
    Abstract available

  136. CHEN X, Wang P, Ou T, Li J, et al
    KLF16 Downregulates the Expression of Tumor Suppressor Gene TGFBR3 to Promote Bladder Cancer Proliferation and Migration.
    Cancer Manag Res. 2022;14:465-477.
    PubMed    
    Abstract available

  137. GAKIS G
    [Adjuvant instillation therapy for non-muscle invasive bladder cancer - beyond BCG und mitomycin C].
    Aktuelle Urol. 2022 Feb 16. doi: 10.1055/a-1677-0952.
    PubMed    
    Abstract available

  138. LONG Y, Wu Z, Yang X, Chen L, et al
    [Retracted] MicroRNA101 inhibits the proliferation and invasion of bladder cancer cells via targeting cFOS.
    Mol Med Rep. 2022;25.
    PubMed    
    Abstract available

  139. WANG Z, Zhu L, Li L, Stebbing J, et al
    Identification of an immune gene-associated prognostic signature in patients with bladder cancer.
    Cancer Gene Ther. 2022 Feb 15. pii: 10.1038/s41417-022-00438.
    PubMed    
    Abstract available

  140. SINGH AK, Praharaj M, Lombardo KA, Yoshida T, et al
    Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer.
    Nat Commun. 2022;13:878.
    PubMed    
    Abstract available

  141. GOLLA V, Shan Y, Farran EJ, Stewart CA, et al
    Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer.
    Urol Oncol. 2022 Feb 12. pii: S1078-1439(22)00025.
    PubMed    
    Abstract available

  142. PEKALA KR, Yabes JG, Bandari J, Yu M, et al
    Corrigendum to 'The centralization of bladder cancer care and its implications for patient travel distance' [Urologic Oncology: Seminars and Original Investigations volume 39 (2021) 834.e.9-834.e.20/9680].
    Urol Oncol. 2022 Feb 12. pii: S1078-1439(21)00567.
    PubMed    


  143. LIU T, Zhang Z, Wang C, Huang H, et al
    BRD4 promotes the migration and invasion of bladder cancer through the Sonic hedgehog signaling pathway and enhances cisplatin resistance.
    Biochem Cell Biol. 2022 Feb 15. doi: 10.1139/bcb-2021-0552.
    PubMed    
    Abstract available

  144. YEARY KHK, Clark N, Saad-Harfouche F, Erwin D, et al
    Cruciferous Vegetable Intervention to Reduce the Risk of Cancer Recurrence in Non-Muscle-Invasive Bladder Cancer Survivors: Development Using a Systematic Process.
    JMIR Cancer. 2022;8:e32291.
    PubMed    
    Abstract available

  145. KORKES F, Timoteo F, Soledade LCB, Bugalho LS, et al
    Stage-Related Cost of Treatment of Bladder Cancer in Brazil.
    Pharmacoecon Open. 2022 Feb 14. pii: 10.1007/s41669-022-00325.
    PubMed    
    Abstract available

  146. LIU CQ, Xia QD, Sun JX, Xu JZ, et al
    Identification and validation of a twelve immune infiltration-related lncRNA prognostic signature for bladder cancer.
    Aging (Albany NY). 2022;14.
    PubMed    
    Abstract available

  147. KUBRAK T, Karakula M, Czop M, Kawczyk-Krupka A, et al
    Advances in Management of Bladder Cancer-The Role of Photodynamic Therapy.
    Molecules. 2022;27.
    PubMed    
    Abstract available

  148. ADAMCZYK P, Poblocki P, Kadlubowski M, Ostrowski A, et al
    A Comprehensive Approach to Clinical Staging of Bladder Cancer.
    J Clin Med. 2022;11.
    PubMed    
    Abstract available

  149. LA CROCE G, Naspro R, Finati M, Pellucchi F, et al
    The Accuracy of Transurethral Bladder Resection in Detecting Bladder Cancer Histological Variants and Their Prognostic Value at Radical Cystectomy.
    J Clin Med. 2022;11.
    PubMed    
    Abstract available

  150. PARDO JC, Sanhueza T, Ruiz de Porras V, Etxaniz O, et al
    Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant Chemotherapy.
    J Clin Med. 2022;11.
    PubMed    
    Abstract available

  151. AUDISIO A, Buttigliero C, Delcuratolo MD, Parlagreco E, et al
    New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond.
    Cells. 2022;11.
    PubMed    
    Abstract available

  152. SHISHIDO SN, Sayeed S, Courcoubetis G, Djaladat H, et al
    Characterization of Cellular and Acellular Analytes from Pre-Cystectomy Liquid Biopsies in Patients Newly Diagnosed with Primary Bladder Cancer.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  153. DEININGER S, Torzsok P, Mitterberger M, Pallauf M, et al
    From Interferon to Checkpoint Inhibition Therapy-A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette-Guerin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC).
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  154. SINGER G, Ramakrishnan VM, Rogel U, Schotzau A, et al
    The Role of New Technologies in the Diagnosis and Surveillance of Non-Muscle Invasive Bladder Carcinoma: A Prospective, Double-Blinded, Monocentric Study of the XPERT(c) Bladder Cancer Monitor and Narrow Band Imaging(c) Cystoscopy.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  155. BOSKOVIC M, Roje B, Chung FF, Gelemanovic A, et al
    DNA Methylome Changes of Muscle- and Neuronal-Related Processes Precede Bladder Cancer Invasiveness.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  156. FASULO V, Paciotti M, Lazzeri M, Contieri R, et al
    Xpert Bladder Cancer Monitor May Avoid Cystoscopies in Patients Under "Active Surveillance" for Recurrent Bladder Cancer (BIAS Project): Longitudinal Cohort Study.
    Front Oncol. 2022;12:832835.
    PubMed    
    Abstract available

  157. LI Y, Cheng X, Yan J, Jiang S, et al
    CTHRC1 facilitates bladder cancer cell proliferation and invasion through regulating the PI3K/Akt signaling pathway.
    Arch Med Sci. 2019;18:183-194.
    PubMed    
    Abstract available

  158. WEI B, Wang Z, Lian Q, Chi B, et al
    hsa_circ_0139402 Promotes Bladder Cancer Progression by Regulating hsa-miR-326/PAX8 Signaling.
    Dis Markers. 2022;2022:9899548.
    PubMed    
    Abstract available

  159. LU Z, Tang F, Li Z, Lai Y, et al
    Prognosis Risk Model Based on Pyroptosis-Related lncRNAs for Bladder Cancer.
    Dis Markers. 2022;2022:7931393.
    PubMed    
    Abstract available

  160. SHIMIZU R, Ohira T, Yagyu T, Yumioka T, et al
    Activation of PPARgamma in bladder cancer via introduction of the long arm of human chromosome 9.
    Oncol Lett. 2022;23:92.
    PubMed    
    Abstract available

  161. KAYID M
    Applications of Bladder Cancer Data Using a Modified Log-Logistic Model.
    Appl Bionics Biomech. 2022;2022:6600278.
    PubMed    
    Abstract available

  162. LU H, Wu J, Liang L, Wang X, et al
    Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer.
    Front Immunol. 2022;13:803355.
    PubMed    
    Abstract available

  163. LI T, Tang Z, Li C, Liu X, et al
    Magnesium-Assisted Cisplatin Inhibits Bladder Cancer Cell Survival by Modulating Wnt/beta-Catenin Signaling Pathway.
    Front Pharmacol. 2022;12:804615.
    PubMed    
    Abstract available

  164. PATTOU M, Baboudjian M, Pinar U, Parra J, et al
    Continent cutaneous urinary diversion with an ileal pouch with the Mitrofanoff principle versus a Miami pouch in patients undergoing cystectomy for bladder cancer: results of a comparative study.
    World J Urol. 2022 Feb 12. pii: 10.1007/s00345-022-03954.
    PubMed    
    Abstract available

  165. FUKUHARA H, Yamamoto S, Lai HW, Karashima T, et al
    Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2(nd) report): reduced bladder recurrence after PDD-TURBT.
    Photodiagnosis Photodyn Ther. 2022 Feb 10:102757.
    PubMed    
    Abstract available

  166. D'SOUZA AA, Tulpule V, Zang PD, Quinn DI, et al
    Bladder cancer: from a therapeutic wilderness to so many options; a guide to practice in a changing landscape.
    Ann Oncol. 2022;33:242-243.
    PubMed    


  167. SHEN Y, Ye H, Zhang D, Yang M, et al
    The role of exosomal CDC6 in the hirudin-mediated suppression of the malignant phenotype of bladder cancer cells.
    Gene. 2022 Feb 9:146269. doi: 10.1016/j.gene.2022.146269.
    PubMed    
    Abstract available

  168. ZHANG J, Dong Y, Shi Z, He H, et al
    P3H4 and PLOD1 expression associates with poor prognosis in bladder cancer.
    Clin Transl Oncol. 2022 Feb 11. pii: 10.1007/s12094-022-02791.
    PubMed    
    Abstract available

  169. LI F, Xu M, Zhuang J
    Dual biomineralized metal-organic frameworks-mediated conversion of chemical energy to electricity enabling portable PEC sensing of telomerase activity in bladder cancer tissues.
    Biosens Bioelectron. 2022;204:114070.
    PubMed    
    Abstract available

  170. TACHIBANA I, Mahmoud M, Abedali ZA, Flack C, et al
    Does pathological sub stratification of T2 bladder cancer predict outcome in a contemporary pure urothelial carcinoma cohort?
    Urol Oncol. 2022 Feb 8. pii: S1078-1439(21)00556.
    PubMed    
    Abstract available

  171. CUI J, Zhu Y, Liu X, Wang W, et al
    Comprehensive analysis of N(6)-methyladenosine regulators with the tumor immune landscape and correlation between the insulin-like growth factor 2 mRNA-binding protein 3 and programmed death ligand 1 in bladder cancer.
    Cancer Cell Int. 2022;22:72.
    PubMed    
    Abstract available

  172. GALLIOLI A, Pradere B, Albisinni S, Moschini M, et al
    Robot-assisted radical cystectomy: towards a future of sexual-sparing surgery?
    Minerva Urol Nephrol. 2021;73:697-699.
    PubMed    


  173. BANI-HANI M, Abdel Majid A, Al-Zubi MT, Al Demour S, et al
    Continuous Saline Bladder Irrigation in Reducing Recurrence and Progression When Compared to Immediate Mitomycin- C Instillation Post- Resection of Bladder Tumor: A Short Communication.
    Asian Pac J Cancer Prev. 2022;23:171-175.
    PubMed    
    Abstract available

  174. MASONE MC
    NMIBC risk factors in patients treated with BCG.
    Nat Rev Urol. 2022;19:67.
    PubMed    


  175. YIN H, Yongkang M, Bao G, Shiming Z, et al
    PD-1 inhibitor toripalimab with gemcitabine as a neoadjuvant therapy for muscle-invasive bladder urothelial carcinoma: A case report.
    Medicine (Baltimore). 2022;101:e28591.
    PubMed    
    Abstract available

  176. THOMAS T
    Bladder EpiCheck for NMIBC.
    Nat Rev Urol. 2022;19:67.
    PubMed    


  177. MAEDA S, Sakai K, Kaji K, Iio A, et al
    Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs.
    Sci Rep. 2022;12:4.
    PubMed    
    Abstract available

  178. DOSNE AG, Valade E, Goeyvaerts N, De Porre P, et al
    Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma.
    Cancer Chemother Pharmacol. 2022;89:151-164.
    PubMed    
    Abstract available

  179. ZOU X, Wei Y, Qi T, Wang X, et al
    A novel 6-gene signature derived from tumor-infiltrating T cells and neutrophils predicts survival of bladder urothelial carcinoma.
    Aging (Albany NY). 2021;13:25496-25517.
    PubMed    
    Abstract available

  180. LIN S, Wang L, Shi Z, Zhu A, et al
    Circular RNA circFLNA inhibits the development of bladder carcinoma through microRNA miR-216a-3p/BTG2 axis.
    Bioengineered. 2021;12:11376-11389.
    PubMed    
    Abstract available

  181. HARVEY M, Chislett B, Perera M, Lawrentschuk N, et al
    Critical shortage in BCG immunotherapy: How did we get here and where will it take us?
    Urol Oncol. 2022;40:1-3.
    PubMed    
    Abstract available

  182. YAMADA S, Abe T, Sazawa A, Katano H, et al
    Comparative study of postoperative complications after radical cystectomy during the past two decades in Japan: Radical cystectomy remains associated with significant postoperative morbidities.
    Urol Oncol. 2022;40:11.
    PubMed    
    Abstract available

  183. HURLE R, Guazzoni G, Colombo P, Santoro A, et al
    Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: Results of a prospective European Multicentre study at 15 months from treatment start.
    Urol Oncol. 2022;40:11.
    PubMed    
    Abstract available

  184. AHN AR, Noh SJ, Hussein UK, Park HS, et al
    FAM83H and Nectin1 expression are related with survival and relapse of bladder urothelial carcinoma patients.
    BMC Urol. 2021;21:143.
    PubMed    
    Abstract available

  185. COMPERAT E, Oszwald A, Wasinger G, Wacquet J, et al
    PD-L1 (SP142) testing is concordant between Benchmark Ultra and Bond-III stainers.
    World J Urol. 2021;39:4067-4071.
    PubMed    
    Abstract available

  186. KOSSAI M, Radulescu C, Adam J, Dziegielewski A, et al
    Plasmacytoid urothelial carcinoma (UC) are luminal tumors with similar CD8+ Tcell density and PD-L1 protein expression on immune cells as compared to conventional UC.
    Urol Oncol. 2022;40:12.
    PubMed    
    Abstract available

  187. MURTHY PB, Lone Z, Corrigan D, Campbell R, et al
    Survival outcomes following radical cystectomy in patients with prior pelvic radiation for prostate cancer: A matched cohort analysis.
    Urol Oncol. 2022;40:10.
    PubMed    
    Abstract available

  188. NECCHI A, Raggi D, Gallina A, Bandini M, et al
    Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition.
    Urol Oncol. 2021;39:734.
    PubMed    
    Abstract available

  189. GOUTAS D, Savvidou K, Vrettou K, Meletis E, et al
    Comparison of conventional and liquid-based cytology using The Paris System for Reporting Urinary Cytology.
    Cytopathology. 2021;32:795-801.
    PubMed    
    Abstract available

  190. ZHOU YW, Long YX, Song K, Liang LB, et al
    Anterior wall adenocarcinoma of bladder with similar clinicopathological and prognostic characteristics as common bladder carcinomas should not be treated as or classified into urachal adenocarcinomas.
    Cancer Med. 2021;10:5415-5428.
    PubMed    
    Abstract available

  191. MORGANS AK, Hepp Z, Shah SN, Shah A, et al
    Real-world burden of illness and unmet need in locally advanced or metastatic urothelial carcinoma following discontinuation of PD-1/L1 inhibitor therapy: A Medicare claims database analysis.
    Urol Oncol. 2021;39:733.
    PubMed    
    Abstract available

  192. MUSANGILE FY, Matsuzaki I, Okodo M, Shirasaki A, et al
    Detection of HPV infection in urothelial carcinoma using RNAscope: Clinicopathological characterization.
    Cancer Med. 2021;10:5534-5544.
    PubMed    
    Abstract available

  193. BEBANE S, Denize J, Goujon A, Meria P, et al
    Perioperative outcomes of transurethral resection for t1 bladder tumors: quality evaluation based on patient, tumor and surgeon criteria.
    World J Urol. 2021;39:4159-4165.
    PubMed    
    Abstract available

  194. SUBIELA JD, Faba OR, Aumatell J, Krajewski W, et al
    Impact of clinical and pathological subtypes of carcinoma in situ (CIS) of the bladder: Lessons learned from long-term follow-up of a series of CIS patients treated with BCG.
    Urol Oncol. 2022;40:9.
    PubMed    
    Abstract available

  195. JANA S, Deo R, Hough RP, Liu Y, et al
    mRNA translation is a therapeutic vulnerability necessary for bladder epithelial transformation.
    JCI Insight. 2021;6.
    PubMed    
    Abstract available

  196. MAAS M, Mischinger J, Comperat E, Scharpf M, et al
    Utility of pT3 substaging in lymph node-negative urothelial carcinoma of the bladder: do pathologic parameters add to prognostic sub-stratification?
    World J Urol. 2021;39:4021-4027.
    PubMed    
    Abstract available

  197. AUMATELL J, Huguet J, Subiela JD, Gaya JM, et al
    Endoscopic exploration directly impacts clinical decision making in the management of patients with suspected upper tract urothelial carcinoma following radical cystectomy.
    Urol Oncol. 2021;39:732.
    PubMed    
    Abstract available

  198. BATEN E, Van der Aa F, Goethuys H, Slabbert K, et al
    A randomized trial regarding antimicrobial prophylaxis (AMP) in transurethral resection of bladder tumor (TURB).
    World J Urol. 2021;39:3839-3844.
    PubMed    
    Abstract available

  199. CALO B, Sanguedolce F, Falagario UG, Chirico M, et al
    Assessing treatment response after intravesical bacillus Calmette-Guerin induction cycle: are routine bladder biopsies necessary?
    World J Urol. 2021;39:3815-3821.
    PubMed    
    Abstract available

  200. KATAYAMA S, Kobayashi Y, Takamoto A, Edamura K, et al
    Impact of paclitaxel, cisplatin, and gemcitabine as first-line chemotherapy in cisplatin-fit and -unfit patients with advanced/metastatic urothelial carcinoma.
    Urol Oncol. 2021;39:731.
    PubMed    
    Abstract available

  201. CHENG HL, Chou LP, Tsai HW, Lee CT, et al
    Urothelial carcinoma with trophoblastic differentiation: Reappraisal of the clinical implication and immunohistochemically features.
    Urol Oncol. 2021;39:732.
    PubMed    
    Abstract available

  202. OSZWALD A, Wasinger G, Larnaudie L, Varinot J, et al
    Pathological reporting of cystectomy lymph nodes: a retrospective analysis of experience in Paris.
    World J Urol. 2021;39:4029-4035.
    PubMed    
    Abstract available

  203. MORMILE R
    Letter to the editor: What about cholesterol as a novel biomarker for bladder and kidney cancer diagnosis and surveillance? In memory of my dad Sossio Mormile.
    Investig Clin Urol. 2021;62:239-240.
    PubMed    


  204. DE VLAMING A, Mathews KG, Hash JA, Keenihan EK, et al
    Creation of a Continent Urinary Bladder Reservoir Vascularized by Omentum as a Possible Surgical Option for Canine Trigonal/Urethral Urothelial Carcinoma.
    J Invest Surg. 2022;35:481-495.
    PubMed    
    Abstract available

  205. ERCOLINO A, Droghetti M, Schiavina R, Bianchi L, et al
    Postoperative outcomes of Fast-Track-enhanced recovery protocol in open radical cystectomy: comparison with standard management in a high-volume center and Trifecta proposal.
    Minerva Urol Nephrol. 2021;73:763-772.
    PubMed    
    Abstract available

  206. TUDERTI G, Mastroianni R, Brassetti A, Bove AM, et al
    Robot-assisted radical cystectomy with intracorporeal neobladder: impact of learning curve and long-term assessment of functional outcomes.
    Minerva Urol Nephrol. 2021;73:754-762.
    PubMed    
    Abstract available

  207. ROUMIGUIE M, Comperat E, Chaltiel L, Nouhaud FX, et al
    PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment.
    World J Urol. 2021;39:4055-4065.
    PubMed    
    Abstract available

  208. SMELSER WW, Jones CP
    Management of anticoagulation and antiplatelet agents in the radical cystectomy patient.
    Urol Oncol. 2021;39:691-697.
    PubMed    
    Abstract available

  209. GUO CC, Al-Ahmadie HA, Flaig TW, Kamat AM, et al
    Contribution of bladder cancer pathology assessment in planning clinical trials.
    Urol Oncol. 2021;39:713-719.
    PubMed    
    Abstract available

  210. JIANG X, Li H, Fang Y, Xu C, et al
    LncRNA PVT1 contributes to invasion and doxorubicin resistance of bladder cancer cells through promoting MDM2 expression and AURKB-mediated p53 ubiquitination.
    Environ Toxicol. 2022 Feb 25. doi: 10.1002/tox.23501.
    PubMed    
    Abstract available

  211. LOBO N, Martini A, Kamat AM
    Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer.
    Expert Rev Anticancer Ther. 2022 Feb 25. doi: 10.1080/14737140.2022.2046466.
    PubMed    
    Abstract available

  212. LIU J, Zhang Z, Liu X, Zhang W, et al
    Predictive role of ferroptosis-related long non-coding RNAs in bladder cancer and their association with immune microenvironment and immunotherapy response.
    World J Surg Oncol. 2022;20:47.
    PubMed    
    Abstract available

  213. LEE SW, Tae BS, Choi YJ, Yoon SM, et al
    A Comparison of the Anesthetic Methods for Recurrence Rates of Bladder Cancer after Transurethral Resection of Bladder Tumors Using National Health Insurance Claims Data of South Korea.
    J Clin Med. 2022;11.
    PubMed    
    Abstract available

  214. SARRIO-SANZ P, Martinez-Cayuelas L, Gil-Guillen VF, Quesada JA, et al
    Mortality Trends Related to Bladder Cancer in Spain, 1999-2018.
    J Clin Med. 2022;11.
    PubMed    
    Abstract available

  215. IBRAHIM NK, Eraky A, Eggers J, Steiert TA, et al
    Detection of Cancer Mutations by Urine Liquid Biopsy as a Potential Tool in the Clinical Management of Bladder Cancer Patients.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  216. HUANG CS, Tsai CH, Yu CP, Wu YS, et al
    Long Noncoding RNA LINC02470 Sponges MicroRNA-143-3p and Enhances SMAD3-Mediated Epithelial-to-Mesenchymal Transition to Promote the Aggressive Properties of Bladder Cancer.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  217. BEEREN I, Goeij L, Dandis R, Vidra N, et al
    Limited Changes in Lifestyle Behaviours after Non-Muscle Invasive Bladder Cancer Diagnosis.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  218. DEL GIUDICE F, Flammia RS, Chung BI, Moschini M, et al
    Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  219. YAO X, Qi X, Wang Y, Zhang B, et al
    Identification and Validation of an Annexin-Related Prognostic Signature and Therapeutic Targets for Bladder Cancer: Integrative Analysis.
    Biology (Basel). 2022;11.
    PubMed    
    Abstract available

  220. CROCETTO F, Pandolfo SD, Aveta A, Martino R, et al
    A Comparative Study of the Triglycerides/HDL Ratio and Pseudocholinesterase Levels in Patients with Bladder Cancer.
    Diagnostics (Basel). 2022;12.
    PubMed    
    Abstract available

  221. SHAHAB U, Habib S, Alsulimani A, Alshammari QT, et al
    N-OH-AABP Modifications in Human DNA May Lead to Auto-Antibodies in Bladder Cancer Subjects.
    Diagnostics (Basel). 2022;12.
    PubMed    
    Abstract available

  222. MAIORANO BA, De Giorgi U, Ciardiello D, Schinzari G, et al
    Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day.
    Biomedicines. 2022;10.
    PubMed    
    Abstract available

  223. NOWAK L, Krajewski W, Malkiewicz B, Szydelko T, et al
    Characteristics and Applications of Canine In Vitro Models of Bladder Cancer in Veterinary Medicine: An Up-to-Date Mini Review.
    Animals (Basel). 2022;12.
    PubMed    
    Abstract available

  224. ABUDUREXITI M, Ma J, Li Y, Hu C, et al
    Clinical Outcomes and Prognosis Analysis of Younger Bladder Cancer Patients.
    Curr Oncol. 2022;29:578-588.
    PubMed    
    Abstract available

  225. ZUO L, Zhu Y, Han J, Liu H, et al
    Circular RNA circSHPRH inhibits the malignant behaviors of bladder cancer by regulating the miR-942/BARX2 pathway.
    Aging (Albany NY). 2022;14.
    PubMed    
    Abstract available

  226. SAH AK, Maharjan B, Adhikari MB, Rana R, et al
    Radical Cystectomy for Intradiverticular Bladder Carcinoma: A Case Report.
    JNMA J Nepal Med Assoc. 2021;59:1069-1071.
    PubMed    
    Abstract available

  227. GUNERI-SOZERI PY, Erkek-Ozhan S
    Identification of the gene expression changes and gene regulatory aspects in ELF3 mutant bladder cancer.
    Mol Biol Rep. 2022 Feb 24. pii: 10.1007/s11033-022-07145.
    PubMed    
    Abstract available

  228. PARRA-GRANDE M, Ore-Arce M, Martinez-Priego L, D'Auria G, et al
    Profiling the Bladder Microbiota in Patients With Bladder Cancer.
    Front Microbiol. 2022;12:718776.
    PubMed    
    Abstract available

  229. RIGHETTO M, Modonutti D, Celso FG, Fulcoli V, et al
    Metabolic syndrome and bladder cancer.
    Panminerva Med. 2022 Feb 22. pii: S0031-0808.22.04641.
    PubMed    
    Abstract available

  230. SHANG W, Peng L, He K, Guo P, et al
    A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer.
    Eur J Nucl Med Mol Imaging. 2022 Feb 21. pii: 10.1007/s00259-022-05701.
    PubMed    
    Abstract available

  231. ZHAN X, Jiang M, Deng W, Liu X, et al
    Development and Validation of a Prognostic Nomogram for Predicting Cancer-Specific Survival in Patients With Lymph Node Positive Bladder Cancer: A Study Based on SEER Database.
    Front Oncol. 2022;12:789028.
    PubMed    
    Abstract available

  232. YANG X, Lv J, Zhou Z, Feng D, et al
    Clinical Application of Circulating Tumor Cells and Circulating Endothelial Cells in Predicting Bladder Cancer Prognosis and Neoadjuvant Chemosensitivity.
    Front Oncol. 2022;11:802188.
    PubMed    
    Abstract available

  233. WESTHOFEN T, Eismann L, Buchner A, Schlenker B, et al
    Baseline Health-related Quality of Life Predicts Bladder Cancer-specific Survival Following Radical Cystectomy.
    Eur Urol Focus. 2022 Feb 17. pii: S2405-4569(22)00045.
    PubMed    
    Abstract available

  234. CHEN CW
    Comment on 'Long noncoding RNA UCA1 promotes glutamine-driven anaplerosis of bladder cancer by interacting with hnRNP I/L to upregulate GPT2 expression' by Chen et al.'".
    Transl Oncol. 2022;18:101372.
    PubMed    
    Abstract available

  235. MICHEL F, Cancrini F, Bensadoun H, Cussenot O, et al
    Incidence of bladder cancer in neuro-urological patients in France: a nationwide study.
    World J Urol. 2022 Feb 19. pii: 10.1007/s00345-022-03955.
    PubMed    
    Abstract available

  236. HOU DY, Zhang NY, Wang MD, Xu SX, et al
    In Situ Constructed Nano-drug Depots through Intracellular Hydrolytic Condensation for Chemotherapy of Bladder Cancer.
    Angew Chem Int Ed Engl. 2022 Feb 18. doi: 10.1002/anie.202116893.
    PubMed    
    Abstract available

  237. FENG Y, Zhong K, Chen R, Zhou W, et al
    Diagnostic accuracy of vesical imaging-reporting and data system (VI-RADS) for the detection of muscle-invasive bladder cancer: a meta-analysis.
    Abdom Radiol (NY). 2022 Feb 18. pii: 10.1007/s00261-022-03449.
    PubMed    
    Abstract available

  238. LI M, Zhang N, Shan W, Guan B, et al
    ALG3 Is a Potential Biomarker for the Prognosis of Bladder Cancer.
    Ann Clin Lab Sci. 2022;52:117-125.
    PubMed    
    Abstract available

  239. MIR MC, Marchioni M, Zargar H, Zargar-Shoshtari K, et al
    Corrigendum to "Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium" [Eur Urol Focus 2021;7:1347-54].
    Eur Urol Focus. 2022 Feb 15. pii: S2405-4569(22)00016.
    PubMed    


  240. KAWASAKI M, Nagase K, Aoki S, Udo K, et al
    Bystander effects induced by the interaction between urothelial cancer cells and irradiated adipose tissue-derived stromal cells in urothelial carcinoma.
    Hum Cell. 2022;35:613-627.
    PubMed    
    Abstract available

  241. SIEFKER-RADTKE AO, Necchi A, Park SH, Garcia-Donas J, et al
    Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
    Lancet Oncol. 2022;23:248-258.
    PubMed    
    Abstract available

  242. HONG T, Piao S, Sun L, Tao Y, et al
    Tumor protein P63 Regulated 1 contributes to inflammation and cell proliferation of cystitis glandularis through regulating the NF-small ka, CyrillicB/cyclooxygenase-2/prostaglandin E2 axis.
    Bosn J Basic Med Sci. 2022;22:100-109.
    PubMed    
    Abstract available

  243. POWLES T, Sridhar SS, Loriot Y, Bellmunt J, et al
    Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial.
    Nat Med. 2021;27:2200-2211.
    PubMed    
    Abstract available

  244. YANAGI M, Hamasaki T, Akatsuka J, Endo Y, et al
    Risk factor analysis of intravesical recurrence after retroperitoneoscopic nephroureterectomy for upper tract urothelial carcinoma.
    BMC Urol. 2021;21:167.
    PubMed    
    Abstract available

  245. LOMBARDO KA, Obradovic A, Singh AK, Liu JL, et al
    BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer.
    J Pathol. 2022;256:223-234.
    PubMed    
    Abstract available

  246. ZAZA SI, Ghasemzadeh A, Bennett KM
    Mycobacterium Bovis Causing Mycotic Aneurysm Secondary to Intravesical Treatment with Bacillus Calmette-Guerin: A Case Report.
    Ann Vasc Surg. 2022;79:437.
    PubMed    
    Abstract available

  247. ZHOU X, Wang F, Wu H, Chen X, et al
    Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells.
    Int J Biol Sci. 2021;17:3456-3475.
    PubMed    
    Abstract available

  248. TANIGUCHI Y, Nishikawa H, Kimata T, Yoshinaga Y, et al
    Reactive Arthritis After Intravesical Bacillus Calmette-Guerin Therapy.
    J Clin Rheumatol. 2022;28:e583-e588.
    PubMed    
    Abstract available

  249. WHELAN P, Kim C, Tabib C, Preminger GM, et al
    Evolution of Single-Use Urologic Endoscopy: Benchtop and Initial Clinical Assessment of a New Single-Use Flexible Cystoscope.
    J Endourol. 2022;36:13-21.
    PubMed    
    Abstract available

  250. VRANIC S, Gatalica Z
    Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers.
    Bosn J Basic Med Sci. 2022;22:14-21.
    PubMed    
    Abstract available

  251. PIZZIGHELLA M, Bruyere F, Peyronnet B, Graffeille V, et al
    The Management of Distal Ureter During Radical Nephroureterectomy Does Not Influence Bladder Recurrence.
    J Endourol. 2022;36:77-82.
    PubMed    
    Abstract available

  252. SUN T, Hutchinson L, Tomaszewicz K, Caporelli ML, et al
    Diagnostic value of a comprehensive, urothelial carcinoma-specific next-generation sequencing panel in urine cytology and bladder tumor specimens.
    Cancer Cytopathol. 2021;129:537-547.
    PubMed    
    Abstract available

  253. FARRAG MA, Ezz MK, Ibrahim NK, Ahmed EK, et al
    Chemopreventive Potential of Myrtenal against Nitrosamine-Initiated, Radiation-Promoted Rat Bladder Carcinogenesis.
    Nutr Cancer. 2022;74:288-298.
    PubMed    
    Abstract available

  254. HUI J, Wang C, Miao Y, Liu R, et al
    The pancancer landscape of Wnt family expression reveals potential biomarkers in urinary system tumors.
    Cancer Gene Ther. 2021;28:1035-1045.
    PubMed    
    Abstract available

  255. KURASHINA R, Ando K, Inoue M, Izumi K, et al
    Platelet-to-Lymphocyte Ratio Predicts the Efficacy of Pembrolizumab in Patients With Urothelial Carcinoma.
    Anticancer Res. 2022;42:1131-1136.
    PubMed    
    Abstract available

  256. CHEN J, Rodopoulou S, Strak M, de Hoogh K, et al
    Long-term exposure to ambient air pollution and bladder cancer incidence in a pooled European cohort: the ELAPSE project.
    Br J Cancer. 2022 Feb 16. pii: 10.1038/s41416-022-01735.
    PubMed    
    Abstract available

  257. JIN K, Yu Y, Zeng H, Liu Z, et al
    CD103(+)CD8(+) tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer.
    Br J Cancer. 2022 Feb 14. pii: 10.1038/s41416-022-01725.
    PubMed    
    Abstract available

  258. SHOHDY KS, Villamar DM, Cao Y, Trieu J, et al
    Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.
    Br J Cancer. 2022;126:430-439.
    PubMed    
    Abstract available

  259. BRAUN A, Abbosh PH
    Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy: A Rare Entity with Unique Genomic Features.
    Eur Urol. 2022 Jan 30. pii: S0302-2838(22)00067.
    PubMed    


  260. BABJUK M
    Re: Long-term Experience with Radiofrequency-induced Hyperthermia Combined with Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer.
    Eur Urol. 2022 Jan 29. pii: S0302-2838(22)00023.
    PubMed    


  261. GROBET-JEANDIN E, Pinar U, Roupret M
    Re: Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study.
    Eur Urol. 2022 Jan 27. pii: S0302-2838(22)00012.
    PubMed    


  262. PARIKH DA, Khaki AR, Williams SB
    Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study.
    Eur Urol. 2022 Feb 4. pii: S0302-2838(22)00017.
    PubMed    


  263. HE P, Zhou X, Chen Z
    Reply to Shun-Fa Hung, Shyi-Chun Yii, and Shiu-Dong Chung's Letter to the Editor re: Zhiwen Chen, Peng He, Xiaozhou Zhou, et al. Preliminary Functional Outcome Following Robotic Intracorporeal Orthotopic Ileal Neobladder Suspension with Round Ligament
    Eur Urol. 2022 Feb 3. pii: S0302-2838(22)00081.
    PubMed    


  264. LEOW JJ, Chong YL, Chang SL, Valderrama BP, et al
    Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy.
    Eur Urol. 2021;79:635-654.
    PubMed    
    Abstract available

  265. HUNG SF, Yii SC, Chung SD
    Re: Zhiwen Chen, Peng He, Xiaozhou Zhou, et al. Preliminary Functional Outcome Following Robotic Intracorporeal Orthotopic Ileal Neobladder Suspension with Round Ligaments in Women with Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eur
    Eur Urol. 2022 Feb 9. pii: S0302-2838(22)00077.
    PubMed    


  266. VAN DER HEIJDEN MS, Loriot Y, Duran I, Ravaud A, et al
    Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.
    Eur Urol. 2021;80:7-11.
    PubMed    
    Abstract available

  267. LI R, Gilbert SM, Kamat AM
    Unraveling the Mechanism of the Antitumor Activity of Bacillus Calmette-Guerin.
    Eur Urol. 2021;80:1-3.
    PubMed    
    Abstract available

  268. SATISH P, Kuusk T, Campain N, Abu-Ghanem Y, et al
    The European Association of Urology COVID Intermediate-priority Group is Poorly Predictive of Pathological High Risk Among Patients with Renal Tumours.
    Eur Urol. 2021;80:265-267.
    PubMed    


  269. DELL'OGLIO P, Andras I, Ortega D, Galfano A, et al
    Impact of the Implementation of the EAU Guidelines Recommendation on Reporting and Grading of Complications in Patients Undergoing Robot-assisted Radical Cystectomy: A Systematic Review.
    Eur Urol. 2021;80:129-133.
    PubMed    
    Abstract available

  270. XU P, Chen B, Xu A, Yuan D, et al
    Initial Experience with Intracorporeal Laparoscopic Radical Cystectomy and Detaenial Sigmoid Neobladder Reconstruction.
    Eur Urol. 2021;79:545-551.
    PubMed    
    Abstract available

  271. DIANATINASAB M, Wesselius A, Salehi-Abargouei A, Yu EYW, et al
    Dietary fats and their sources in association with the risk of bladder cancer: A pooled analysis of 11 prospective cohort studies.
    Int J Cancer. 2022 Feb 19. doi: 10.1002/ijc.33970.
    PubMed    
    Abstract available

  272. LEOW JJ, Yong DZ, Chia PL
    Editorial Comment to Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer: Results from the International Robotic Cystectomy Consortium.
    Int J Urol. 2022 Feb 10. doi: 10.1111/iju.14818.
    PubMed    


  273. YANG T, Liang H, Pei X, Zhang N, et al
    Substratification of patients with highest-risk non-muscle invasive bladder cancer helps to identify the candidates for immediate radical cystectomy: A two-center study.
    Int J Urol. 2022 Feb 5. doi: 10.1111/iju.14808.
    PubMed    
    Abstract available

  274. TAOKA R, Sugimoto M
    Editorial Comment to Substratification of patients with highest-risk non-muscle invasive bladder cancer helps to identify the candidates for immediate radical cystectomy: A two-center study.
    Int J Urol. 2022 Feb 15. doi: 10.1111/iju.14828.
    PubMed    


  275. IQBAL U, Houenstein HA, Elsayed AS, Jing Z, et al
    Ileal conduit versus neobladder: A propensity score-matched analysis of the effect on renal function.
    Int J Urol. 2022;29:158-163.
    PubMed    
    Abstract available

  276. LIN MY, Niu SW, Li WM, Lee HL, et al
    Incidence and survival variations of upper tract urothelial cancer in Taiwan (2001-2010).
    Int J Urol. 2022;29:121-127.
    PubMed    
    Abstract available

  277. PARAJULI P, Luitel BR, Pradhan MM, Chapagain S, et al
    Clinicopathological patterns of bladder carcinoma over 1 year: experience from University Hospital of Nepal.
    Int Urol Nephrol. 2021;53:2289-2294.
    PubMed    
    Abstract available

  278. YORULMAZ EM, Yilmaz Y, Kose O, Akin Y, et al
    Investigation of the causes of BCG refractory in patients treated with intracavitary BCG as secondary treatment in superficial bladder tumors with transurethral resection.
    Int Urol Nephrol. 2022;54:533-540.
    PubMed    
    Abstract available

  279. REHME C, Fritsch B, Thomas L, Istin S, et al
    Clinical outcome and quality of life in octogenarian patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy or transurethral resection of the bladder tumor: a retrospective analysis of 143 patients.
    Int Urol Nephrol. 2022;54:71-79.
    PubMed    
    Abstract available

  280. BAKER SC, Mason AS, Slip RG, Skinner KT, et al
    Induction of APOBEC3-mediated genomic damage in urothelium implicates BK polyomavirus (BKPyV) as a hit-and-run driver for bladder cancer.
    Oncogene. 2022 Feb 22. pii: 10.1038/s41388-022-02235.
    PubMed    
    Abstract available

  281. LEON P, Saint F, Audenet F, Roumiguie M, et al
    [Guidelines from the cancer committee of the French Association of Urology (CC-AFU) for adequate intravesical instillations of Mitomycin C, Epirubicin, and BCG for non-muscle invasive bladder cancer].
    Prog Urol. 2022 Feb 9. pii: S1166-7087(22)00011.
    PubMed    
    Abstract available

  282. WEINHOLD P, Jokisch F, Schulz GB, Buchner A, et al
    Clinical Implication of Borderline CT-Morphological Metastatic Spread in Bladder Cancer: What You See Is Not Always What You Got.
    Urol Int. 2022 Feb 3:1-10. doi: 10.1159/000521857.
    PubMed    
    Abstract available

  283. VOLZ Y, Pfitzinger PL, Eismann L, Ebner B, et al
    Prognostic Value of Pretreatment Inflammatory Markers in Patients Receiving Radical Cystectomy for Urothelial Bladder Cancer: Does Age Matter?
    Urol Int. 2022 Feb 8:1-8. doi: 10.1159/000521829.
    PubMed    
    Abstract available

  284. KAMECKI H, Debowska M, Nyk L, Przewor A, et al
    The Clinical Features of Incidentally Diagnosed Urothelial Bladder Cancer: A Retrospective Data Analysis.
    Urol Int. 2022 Feb 11:1-8. doi: 10.1159/000521684.
    PubMed    
    Abstract available

  285. DALIMOV Z, Iqbal U, Jing Z, Wiklund P, et al
    Intracorporeal Versus Extracorporeal Neobladder After Robot-assisted Radical Cystectomy: Results From the International Robotic Cystectomy Consortium.
    Urology. 2022;159:127-132.
    PubMed    
    Abstract available

  286. HINATA N, Hussein AA, Bando Y, Terakawa T, et al
    Histologic Investigation of the Female Vesicourethral Junction and Adjacent Tissues for Nerve-sparing Radical Cystectomy.
    Urology. 2021;149:161-167.
    PubMed    
    Abstract available

  287. ELSAYED AS, Ozair S, Iqbal U, Mostowy M, et al
    Prevalence and Predictors of Venous Thromboembolism After Robot-Assisted Radical Cystectomy.
    Urology. 2021;149:146-153.
    PubMed    
    Abstract available

  288. ALDHAAM NA, Elsayed AS, Hussein AA, Siam A, et al
    Impact of Perioperative Multidisciplinary Rehabilitation Pathway on Early Outcomes after Robot-assisted Radical Cystectomy: A Matched Analysis.
    Urology. 2021;147:155-161.
    PubMed    
    Abstract available

  289. AVULOVA S, Wittmann D
    Optimizing Women's Sexual Function and Sexual Experience After Radical Cystectomy.
    Urology. 2021;151:138-144.
    PubMed    
    Abstract available

  290. SMITH AL, Weissbart SJ
    Gynecologic Considerations for the Urologic Surgeon.
    Urology. 2021;150:116-124.
    PubMed    
    Abstract available

  291. CRUZ AP, Chelluri R, Ramchandani P, Guzzo TJ, et al
    Post-cystectomy Enterocele: A Case Series and Review of the Literature.
    Urology. 2021;150:180-187.
    PubMed    
    Abstract available

  292. KIM AH, Ruel NH, Yamzon J, Zhumkhawala AA, et al
    Novel Antibiotic-Irrigating Wound Protector Reduces Infectious Complications in Robot-Assisted Radical Cystectomy with Extracorporeal Urinary Diversion.
    Urology. 2022;159:160-166.
    PubMed    
    Abstract available

  293. STANGL-KREMSER J, Ahmadi H, Derstine B, Wang SC, et al
    Psoas Muscle Mass can Predict Postsurgical Outcomes in Patients Who Undergo Radical Cystectomy and Urinary Diversion Reconstruction.
    Urology. 2021;158:142-149.
    PubMed    
    Abstract available

  294. LOH-DOYLE JC, Bhanvadia SK, Han J, Ghodoussipour S, et al
    Patient Reported Sexual Function Outcomes in Male Patients Following Open Radical Cystoprostatectomy and Urinary Diversion.
    Urology. 2021;157:161-167.
    PubMed    
    Abstract available

  295. WESTERMAN ME, Bree KK, Kokorovic A, Frank J, et al
    What Women Want: Radical Cystectomy and Perioperative Sexual Function Educational Needs.
    Urology. 2021;157:181-187.
    PubMed    
    Abstract available

  296. MURTHY PB, Lone Z, Munoz Lopez C, Ericson JZK, et al
    Comparison of Oncologic Outcomes Following Open and Robotic-assisted Radical Cystectomy with both Extracorporeal and Intracorporeal Urinary Diversion.
    Urology. 2021;154:184-190.
    PubMed    
    Abstract available

  297. KLEIN GT, Ajay D, Volk RJ, Leal V, et al
    Living With Urinary Diversions: Patient Insights to Improve the Perioperative Experience.
    Urology. 2021;152:190-194.
    PubMed    
    Abstract available

  298. KERN SQ, Speir RW, Tong Y, Kaimakliotis H, et al
    Longitudinal Health Related Quality of Life After Open Radical Cystectomy: Comparison of Ileal Conduit, Indiana Pouch, and Orthotopic Neobladder.
    Urology. 2021;152:184-189.
    PubMed    
    Abstract available

  299. KNORR JM, Ericson KJ, Zhang JH, Murthy P, et al
    Comparison of Major Complications at 30 and 90 Days Following Radical Cystectomy.
    Urology. 2021;148:192-197.
    PubMed    
    Abstract available

  300. GUL ZG, Liaw CW, Mehrazin R
    Gender Differences in Incidence, Diagnosis, Treatments, and Outcomes in Clinically Localized Bladder and Renal Cancer.
    Urology. 2021;151:176-181.
    PubMed    
    Abstract available

  301. YANG H, Zhang Z, Zhao K, Zhang Y, et al
    Extraperitoneal Laparoscopic Radical Cystectomy With Preservation of Fertility for the Treatment of Ewing Sarcoma: The First Report of a Reliable Surgical Method.
    Urology. 2022;159:241-246.
    PubMed    
    Abstract available

  302. VASSANTACHART A, Daneshmand S, Cai J, Miranda G, et al
    Feasibility and Outcomes of Orthotopic Ileal Neobladder Reconstruction Following Pelvic Irradiation.
    Urology. 2021;148:198-202.
    PubMed    
    Abstract available

  303. WAHLIN S, Boman K, Moran B, Nodin B, et al
    Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity.
    BMC Cancer. 2022;22:131.
    PubMed    
    Abstract available

  304. KIM KS, Kim SH, Cho HJ, Sur HJ, et al
    Holmium laser-assisted laparoscopic partial cystectomy for bladder cancer: a single-institutional pilot study with technical feasibility and short-term oncological outcome.
    BMC Cancer. 2022;22:195.
    PubMed    
    Abstract available

  305. HEMMINKI K, Forsti A, Hemminki A, Ljungberg B, et al
    Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years.
    PLoS One. 2022;17:e0261124.
    PubMed    
    Abstract available

  306. KONG N, Zhang R, Wu G, Sui X, et al
    Intravesical delivery of KDM6A-mRNA via mucoadhesive nanoparticles inhibits the metastasis of bladder cancer.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;